

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, with Express Mail Label No. EL523936059US on this date: 2-16-01 By: G. Barclay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Guittard, George V., et al.

Serial No.: Not Assigned

Filed: Herewith

For: Method for the
Management of
Incontinence

Group Art Unit: Not Assigned

Examiner:

Preliminary Amendment

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir/Madam:

PRELIMINARY AMENDMENT

Please amend the application filed herewith as follows:

IN THE CLAIMS

Cancel claims 2-31.

Add new claims 32 and 33 as follows:

32. A pharmaceutical dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salts, the dosage form being adapted to be administered once-a-day and release the member at a controlled and sustained rate.

33. The dosage form of claim 32 wherein the controlled and sustained rate is substantially zero order.

IN THE SPECIFICATION

On page 1, line 4, after "application" insert -- is a continuation of U.S. Patent Application Serial No. 09/280,309, filed March 29, 1999, now US Patent No. , which - -.


REMARKS

In accordance with usual practice, please calculate the filing fee in the above-identified accompanying application after cancellation of claims 2-31. Upon entrance of the amendment, claims 1 and 32-33 will be in the application.

The specification is being amended to identify the related parent application of which this application is a continuation.

Respectfully submitted,

Dated: 2-16-01


John A. Dhuey
Registration Number 26,265
Attorney for the Applicants

ALZA Corporation
1900 Charleston Road
P.O. Box 7210
Mountain View, CA 94039-7210
650-564-5699